Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 187 citing articles:

A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1542-1556
Open Access | Times Cited: 1428
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1966-1986
Open Access | Times Cited: 1268
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai–Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 652
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 1, pp. 101133-101133
Open Access | Times Cited: 559
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 483
Exploring the landscape of steatotic liver disease in the general US population
Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, et al.
Liver International (2023) Vol. 43, Iss. 11, pp. 2425-2433
Open Access | Times Cited: 92
Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
Youwei Zheng, Shiting Wang, Jialiang Wu, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 47
The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease
Aldo Grefhorst, Ivo P. van de Peppel, Lars Emil Larsen, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 97
The NAFLD‐MAFLD debate: Eminence vs evidence
Yasser Fouad, Reda Elwakil, Medhat Elsahhar, et al.
Liver International (2020) Vol. 41, Iss. 2, pp. 255-260
Open Access | Times Cited: 92
Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH
Leigh Goedeke, Gerald I. Shulman
Molecular Metabolism (2021) Vol. 46, pp. 101178-101178
Open Access | Times Cited: 71
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Gabriel Tayguara Silveira Guerreiro, Larisse Longo, Mariana Fonseca, et al.
Hepatology International (2021) Vol. 15, Iss. 2, pp. 380-391
Closed Access | Times Cited: 58
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 533-546
Open Access | Times Cited: 50
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Olufunto O. Badmus, Terry D. Hinds, David E. Stec
Current Hypertension Reports (2023) Vol. 25, Iss. 8, pp. 151-162
Open Access | Times Cited: 41
Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
Georg Semmler, Lorenz Balcar, Sarah Wernly, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 36
Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003–2018
Zhilan Xie, Ruxianguli Aimuzi, Mingyu Si, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
Associations of thyroid feedback quantile-based index with diabetes in euthyroid adults in the United States and China
Heng Wan, Genfeng Yu, Yajun He, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 10
Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
K. L. Raikhelson, M. V. Maevskaya, М. С. Жаркова, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2024) Vol. 34, Iss. 2, pp. 35-44
Open Access | Times Cited: 10
The role of the advanced lung cancer inflammation index (ALI) in the risk of liver fibrosis and mortality among US adult MAFLD patients: a cross-sectional study of NHANES 1999–2018
Chunchun Yu, L. Chen, Wanting Hu, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding
Federica Cioffi, Antonia Giacco, Giuseppe Petito, et al.
Genes (2022) Vol. 13, Iss. 2, pp. 315-315
Open Access | Times Cited: 35
From NAFLD to MAFLD: Nurse and allied health perspective
Michelle Clayton, Núria Fabrellas, Jinkai Luo, et al.
Liver International (2021) Vol. 41, Iss. 4, pp. 683-691
Open Access | Times Cited: 40
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—Rather a Bystander Than a Driver of Mortality
Georg Semmler, Sarah Wernly, Sebastian Bachmayer, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 106, Iss. 9, pp. 2670-2677
Open Access | Times Cited: 40
Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
Rasmus Hvidbjerg Gantzel, Mikkel Breinholt Kjær, Tea Lund Laursen, et al.
Frontiers in Medicine (2021) Vol. 7
Open Access | Times Cited: 36
Pathology of non-alcoholic fatty liver disease
Ivana Cataldo, Samantha Sarcognato, Diana Sacchi, et al.
Pathologica (2021) Vol. 113, Iss. 3, pp. 194-202
Open Access | Times Cited: 36
Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population
Satoko Takahashi, Marenao Tanaka, Yukimura Higashiura, et al.
Endocrine Journal (2021) Vol. 69, Iss. 4, pp. 463-471
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top